Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.3
2.4
Journals
Veterinary Sciences
Special Issues
Soft-Tissue Sarcomas in Dogs
share announcement

Soft-Tissue Sarcomas in Dogs

A special issue of Veterinary Sciences (ISSN 2306-7381).

Deadline for manuscript submissions: 15 May 2024 | Viewed by 11719

Special Issue Editors

Dr. Jane Dobson

E-Mail Website
Guest Editor
Department of Veterinary Medicine, University of Cambridge, Cambridge CB3 0ES, UK
Interests: veterinary and comparative oncology; chemotherapy; radiotherapy; breed-associated tumours
Dr. Alison Hayes

E-Mail Website
Guest Editor
Queen’s Veterinary School Hospital, Department of Veterinary Medicine, University of Cambridge, Cambridge CB3 0ES, UK
Interests: veterinary and comparative oncology; chemotherapy; radiotherapy; feline sarcomas and carcinomas
Dr. Kate Hughes

E-Mail Website
Guest Editor
Department of Veterinary Medicine, University of Cambridge, Cambridge CB3 0ES, UK
Interests: veterinary and comparative oncology; anatomic pathology; mammary tumours; rabbit pathology

Special Issue Information

Dear Colleagues,

In contrast to humans, where soft-tissue sarcomas are rare tumours, soft-tissue sarcomas are relatively common tumours in dogs, where they represent 10–20% of all neoplasms. The diagnosis, classification, and management of canine soft-tissue sarcomas has evolved over many years, and the present Special Issue seeks to encapsulate some of these changes and presents the current, state-of-the-art understanding of these tumours in a series of review articles and case studies. Furthermore, the review explores comparative aspects of both human and canine soft-tissue sarcomas, arguing the case for canine tumours being an excellent model for exploring innovative and novel approaches to the treatment of the disease in all species.

Dr. Jane Dobson
Dr. Alison Hayes
Dr. Kate Hughes
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Veterinary Sciences is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • soft-tissue sarcoma
  • canine
  • pathology
  • classification
  • diagnosis
  • management

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

17 pages, 1421 KiB  
Article
Development of a Nomogram to Predict the Outcome for Patients with Soft Tissue Sarcoma
by Jonathan P. Bray and John S. Munday
Vet. Sci. 2023, 10(4), 266; https://doi.org/10.3390/vetsci10040266 - 29 Mar 2023
Cited by 1 | Viewed by 1512
Abstract
Soft tissue sarcomas (STSs) are common cutaneous or subcutaneous neoplasms in dogs. Most STSs are initially treated by surgical excision, and local recurrence may develop in almost 20% of patients. Currently, it is difficult to predict which STS will recur after excision, but [...] Read more.
Soft tissue sarcomas (STSs) are common cutaneous or subcutaneous neoplasms in dogs. Most STSs are initially treated by surgical excision, and local recurrence may develop in almost 20% of patients. Currently, it is difficult to predict which STS will recur after excision, but this ability would greatly assist patient management. In recent years, the nomogram has emerged as a tool to allow oncologists to predict an outcome from a combination of risk factors. The aim of this study was to develop a nomogram for canine STSs and determine if the nomogram could predict patient outcomes better than individual tumour characteristics. The current study provides the first evidence in veterinary oncology to support a role for the nomogram to assist with predicting the outcome for patients after surgery for STSs. The nomogram developed in this study accurately predicted tumour-free survival in 25 patients but failed to predict recurrence in 1 patient. Overall, the sensitivity, specificity, positive predictive, and negative predictive values for the nomogram were 96%, 45%, 45%, and 96%, respectively (area under the curve: AUC = 0.84). This study suggests a nomogram could play an important role in helping to identify patients who could benefit from revision surgery or adjuvant therapy for an STS. Full article
(This article belongs to the Special Issue Soft-Tissue Sarcomas in Dogs)
►▼ Show Figures

Figure 1

16 pages, 3381 KiB  
Article
Immunostaining for VEGF and Decorin Predicts Poor Survival and Recurrence in Canine Soft Tissue Sarcoma
by Jonathan P. Bray, Matthew R. Perrott and John S. Munday
Vet. Sci. 2023, 10(4), 256; https://doi.org/10.3390/vetsci10040256 - 28 Mar 2023
Viewed by 1441
Abstract
The aim of this study was to investigate whether using immunohistochemistry to detect the angiogenic proteins vascular endothelial growth factor (VEGF) and decorin can help predict the risk of local recurrence of, or death from, canine soft tissue sarcoma (STS). VEGF and decorin [...] Read more.
The aim of this study was to investigate whether using immunohistochemistry to detect the angiogenic proteins vascular endothelial growth factor (VEGF) and decorin can help predict the risk of local recurrence of, or death from, canine soft tissue sarcoma (STS). VEGF and decorin were detected using validated immunohistochemical methods on 100 formalin-fixed paraffin-embedded samples of canine STS. The tumours had been resected previously, with clinical outcome determined by questionnaire. Each slide was assessed by light microscopy and the pattern of immunostaining with VEGF and decorin determined. Patterns of immunostaining were then analysed to detect associations with outcome measures of local recurrence and tumour-related death. High VEGF immunostaining was significantly (p < 0.001) associated with both increased local recurrence and reduced survival time. The distribution of decorin immunostaining within the tumour was significantly associated with survival time (p = 0.04) and local tumour recurrence (p = 0.02). When VEGF and decorin scores were combined, STS with both high VEGF and low decorin immunostaining were more likely to recur or cause patient death (p < 0.001). The results of this study suggest that immunostaining of VEGF and decorin may help predict the risk of local recurrence of canine STS. Full article
(This article belongs to the Special Issue Soft-Tissue Sarcomas in Dogs)
►▼ Show Figures

Figure 1

Review

Jump to: Research

10 pages, 235 KiB  
Review
Sarcoma Predisposition in Dogs with a Comparative View to Human Orthologous Disease
by Maja L. Arendt and Jane M. Dobson
Vet. Sci. 2023, 10(7), 476; https://doi.org/10.3390/vetsci10070476 - 21 Jul 2023
Viewed by 1585
Abstract
Sarcomas are malignant tumors arising from the embryonic mesodermal cell lineage. This group of cancers covers a heterogenous set of solid tumors arising from soft tissues or bone. Many features such as histology, biological behavior and molecular characteristics are shared between sarcomas in [...] Read more.
Sarcomas are malignant tumors arising from the embryonic mesodermal cell lineage. This group of cancers covers a heterogenous set of solid tumors arising from soft tissues or bone. Many features such as histology, biological behavior and molecular characteristics are shared between sarcomas in humans and dogs, suggesting that human sarcoma research can be informative for canine disease, and that dogs with sarcomas can serve as relevant translational cancer models, to aid in the understanding of human disease and cancer biology. In the present paper, risk factors for the development of sarcoma in dogs are reviewed, with a particular focus on recent advances in clinical genetics, and on the identification of simple and complex genetic risk factors with a comparison with what has been found in human orthologous disease. Full article
(This article belongs to the Special Issue Soft-Tissue Sarcomas in Dogs)
17 pages, 2910 KiB  
Review
Molecular Profile of Canine Hemangiosarcoma and Potential Novel Therapeutic Targets
by Pedro Antônio Bronhara Pimentel, Antonio Giuliano, Paweł Marek Bęczkowski and Rodrigo Dos Santos Horta
Vet. Sci. 2023, 10(6), 387; https://doi.org/10.3390/vetsci10060387 - 05 Jun 2023
Viewed by 6076
Abstract
Canine hemangiosarcoma (HSA) is a relatively common neoplasia, occurring mainly in the skin, spleen, liver and right atrium. Despite the numerous studies investigating the treatment of canine HSA, no significant improvement in survival has been achieved in the last 20 years. Advancements in [...] Read more.
Canine hemangiosarcoma (HSA) is a relatively common neoplasia, occurring mainly in the skin, spleen, liver and right atrium. Despite the numerous studies investigating the treatment of canine HSA, no significant improvement in survival has been achieved in the last 20 years. Advancements in genetic and molecular profiling presented molecular similarities between canine HSA and human angiosarcoma. It could therefore serve as a valuable model for investigating new and more effective treatments in people and dogs. The most common genetic abnormalities in canine HSA have been found in the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) and neuroblastoma RAS viral oncogene homolog (NRAS) pathways. Mutations are also found in tumor protein p53 (TP53), phosphatase and tensin homolog (PTEN) and cyclin dependent kinase inhibitor 2A (CDKN2A). Known abnormal protein expression could be exploited to trial new target treatments that could be beneficial for both canine and human patients. Despite the high expression of vascular endothelial growth factor (VEGF) and its receptor (VEGFR), no correlation with overall survival time has ever been found. In this review, we explore the most recent developments in molecular profiling in canine HSA and discuss their possible applications in the prognosis and treatment of this fatal disease. Full article
(This article belongs to the Special Issue Soft-Tissue Sarcomas in Dogs)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop